Eric Venker Sells 416,182 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 416,182 shares of the business’s stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $14.99, for a total value of $6,238,568.18. Following the completion of the transaction, the chief executive officer owned 2,115,959 shares in the company, valued at $31,718,225.41. This trade represents a 16.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Eric Venker also recently made the following trade(s):

• On Tuesday, September 23rd, Eric Venker sold 611,000 shares of Roivant Sciences stock. The shares were sold at an average price of $14.83, for a total value of $9,061,130.00.
• On Friday, September 19th, Eric Venker sold 683,818 shares of Roivant Sciences stock. The shares were sold at an average price of $14.95, for a total value of $10,223,079.10.
• On Wednesday, August 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.72, for a total value of $1,172,000.00.
• On Monday, July 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.52, for a total value of $1,152,000.00.

Roivant Sciences Stock Performance

Shares of NASDAQ ROIV opened at $14.70 on Thursday. The firm has a market cap of $10.04 billion, a price-to-earnings ratio of -21.00 and a beta of 1.15. The business’s 50-day simple moving average is $12.41 and its 200-day simple moving average is $11.37. Roivant Sciences Ltd. has a 52 week low of $8.73 and a 52 week high of $16.05.

Institutional Trading of Roivant Sciences

A number of hedge funds have recently modified their holdings of ROIV. Vident Advisory LLC lifted its position in shares of Roivant Sciences by 98.7% in the 4th quarter. Vident Advisory LLC now owns 32,039 shares of the company’s stock worth $379,000 after acquiring an additional 15,918 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Roivant Sciences by 4.5% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,411,466 shares of the company’s stock worth $28,528,000 after acquiring an additional 104,288 shares during the period. GF Fund Management CO. LTD. bought a new stake in shares of Roivant Sciences in the 4th quarter worth approximately $181,000. Jefferies Financial Group Inc. bought a new stake in shares of Roivant Sciences in the 4th quarter worth approximately $473,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Roivant Sciences in the 4th quarter worth approximately $194,000. Institutional investors own 64.76% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Guggenheim increased their price objective on Roivant Sciences from $15.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, September 18th. Bank of America increased their price objective on Roivant Sciences from $12.00 to $16.50 and gave the company a “neutral” rating in a report on Thursday, September 18th. Leerink Partners increased their price objective on Roivant Sciences from $18.00 to $22.00 and gave the company an “outperform” rating in a report on Thursday, September 18th. Jefferies Financial Group increased their target price on Roivant Sciences from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Thursday, September 18th. Finally, JPMorgan Chase & Co. increased their target price on Roivant Sciences from $16.00 to $20.00 and gave the company an “overweight” rating in a research note on Thursday, September 18th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $19.94.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.